Anti-metastatic agents predicated upon polyamine macrocylic conjugates
USRE47750E1 · kind E1 · reissue
0Cited by
3References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 22, 2018 |
| Grant date | Dec 3, 2019 |
| Priority date | — |
| Expiry date | Feb 22, 2038 |
Classification
- Technology area (CPC —)General
Abstract
Disclosed herein are novel motuporamine compounds that act as anti-metastatic agents with low toxicity and high anti-migration activity. The non-toxic, anti-metastatic agents may be given to patients with potential or actual metastatic cancers, such as pancreatic cancers, alone in combination with known and/or new therapies to help block the growth and spread of tumor(s).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.